|Last Price$176.24||Day Change (%)3.15%|
|Open Price$175.32||Day Change ($)5.39|
|Day Range170.03–176.29||52-Week Range150.06–208.88|
As of Wed 9/2/2015 5:00:00 PM | USD
European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)
European Commission Grants Marketing Authorization for Strensiq™ (asfotase alfa) for the Treatment of Patients with Pediatric-Onset Hypophosphatasia (HPP)
UPDATE: Charting the U.S. markets' technical cross currents
Charting the U.S. markets' technical cross currents
Blueprint Medicines Reports Second Quarter 2015 Financial Results and Provides Business Update
We crunch the numbers to see which stocks are most widely held among analyst-recommended large-cap funds.
Ownership data provide a look at who else owns the company.
Alexion's diversifying pipeline and focus on attractive rare-disease markets are strengthening its competitive position.
Standing out in a good year for stocks.
Buying a country or sector fund isn't as easy as it seems.